ABSTRACT-The efficacy of NKH477, a novel water-soluble forskolin derivative, in improving cardiac failure was assessed in dog heart-lung preparations. Cardiac func tions depressed by pentobarbital, propranolol or verapamil so that cardiac output had been reduced by about 40-50% of the respective control were all improved by NKH477 (10-100/dg) in a dose-dependent manner. With 100 ,ug NKH477, almost complete restoration of cardiac performance was attained in the respective cardiac fail ures. In the combination of NKH477 with ouabain (30,ug), 30,ug of NKH477 com pletely restored the cardiac function depressed by pentobarbital, associated with a slight but not significant increase in heart rate. No arrhythmias were induced by any of the NKH477 doses used in the experiments. These results suggest that NKH477 should be subjected to clinical trials in the treatment of cardiac failure.
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Cardiac glycosides have been widely used for the treatment of congestive heart failure. However, their narrow margin of safety and propensity to produce fatal arrhythmias have imposed serious problems on use. Recently, many novel nonglycoside cardiotonic drugs which include orally active fl-adrenoceptor agonists and phosphodiesterase inhibitors have been developed (1). Most of these drugs pro duce their positive inotropic action by increas ing intracellular cyclic AMP in the myocar dium. Forskolin (Fig. 1) , a diterpene obtained from Coleus forskohlii, also increases the in tracellular cyclic AMP level in the myocar dium and exhibits a positive inotropic effect (2). However, forskolin has not been available as a drug since it has poor water-solubility and low oral activity, although the unique ability of forskolin has been demonstrated to stimu late adenylate cyclase directly, not through a ,B-adrenoceptor-mediated mechanism (3, 4).
NKH477, 6-(3-dimethylaminopropionyl)fors kolin hydrochloride (Fig. 1) , is a novel water soluble forskolin derivative (5). The car diovascular profile of NKH477 was briefly re ported previously (6). NKH477, like forskolin, stimulated adenylate cyclase directly and pro duced positive inotropic and vasodilator effects (6). The present experiments were de signed to obtain information about the effects of NKH477 on the failing heart. We used the dog heart-lung preparation in which cardiac failure was produced by pentobarbital, propra nolol or verapamil.
MATERIALS AND METHODS
The heart-lung preparation employed in this study was the same as described elsewhere in detail (7). Twenty-four heart-lung preparations were prepared from mongrel dogs of either sex, weighing 10-15 kg and anesthetized with sodium pentobarbital (30 mg/kg, i.v. Competence tests were also performed in each failing heart. NKH477 (10-100,ug) was administered into the blood reservoir in a cumulative manner, and a competence test was carried out after each dose of NKH477.
In the experiment of pentobarbital-induced heart failure, effects of the combination of NKH477 with ouabain were also examined. In that case, ouabain (30 ,u g) was administered first and then NKH477 (30-100 ,ug) adminis tered later. The drugs used were sodium pentobarbital (Tokyo Kasei), propranolol (Sigma), verapa mil (Sigma), ouabain (Aldrich) and NKH477, 6-(3-dimethylaminopropionyl)forskolin hydro chloride (Nippon Kayaku).
The results were expressed as the mean value ± S.E.M., unless otherwise noted. Sta tistical analysis was performed by analysis of variance and significant differences (P < 0.05) were judged using Dunnett's test. 
RESULTS
Pentobarbital-induced heart failure Cardiac function curves obtained from all six experiments are presented in Fig. 2 . Be fore the administration of sodium pentobarbi tal, the left atrial pressure and cardiac output were 4.7 ± 0.5 mmHg and 571 ± 55 ml/min, respectively, under baseline conditions (n = 6). On elevation of the level of blood in the reservoir to 10 cm above the baseline, left at rial pressure and cardiac output rose to 7.6 ± 0.9 mmHg and 1077 ± 59 ml/min, respective ly. After the administration of sodium pento barbital (129 ± 37 mg, mean value ± S.D.), the left atrial pressure and cardiac output were 8.0 ± 0.9 mmHg and 379 ± 36 ml/min under baseline conditions and 15.6 ± 2.0 mmHg and 723 ± 35 ml/min when the level of blood in the reservoir was elevated by 10 cm, respec tively. Consequently, the cardiac function curve was shifted downwards and to the right. Following the addition of NKH477 (10 100 ,ug), the cardiac function curve depressed by pentobarbital was shifted upwards and to the left in a dose-dependent manner. With 100 ,ug NKH477, almost complete improvement of the depressed cardiac function curve was accomplished.
Under baseline conditions, the right atrial pressure rose from 1.8 ± 0.4 cmH2O in the control to 3.8 ± 0.4 cmH2O in cardiac failure preparations. The elevated right atrial pres sure was lowered with NKH477 (10 100,ug) in a dose-dependent manner and completely improved with 100 ,up, NKH477, as shown in Fig. 3A .
The heart rate was 148 ± 6 beats/min in the control and decreased to 132 ± 10 beats/min in the failing heart. The heart rate was in creased with increasing doses of NKH477 and with 100 ,u g, the increase was about 28% of the control value (Fig. 3B) .
The decrease in LV dP/dtmax in the failing heart and its improvement with NKH477 are presented in Fig. 3C . LV dP/dtmax decreased in the failing heart was increased with increas ing doses of NKH477; and with 100,ug, LV dP/dtmax was increased beyond the control value.
No arrhythmias were induced by NKH477 in any doses used.
The combination of NKH477 with ouabain Effects of the combination of NKH477 with ouabain (30 ,ug) were also examined on the pentobarbital-induced heart failure. The de pressed cardiac function curve in the failing heart was partially improved with 30 jig oua bain. Following the addition of NKH477 (30 100 pg), the cardiac function curve was further improved in a dose-dependent manner and almost complete improvement was accomplished with 30 ,u g NKH477. The cardiac function curve was improved beyond the control value with 100 pug NKH477 (Fig. 4) . No arrhythmias were induced by NKH477, even at 100,ug.
The elevated right atrial pressure and the decreased LV dP/dtmax in the failing heart were also partially improved with 30,ug oua bain and further improved with NKH477 (30 100 ,ug) in a dose-dependent manner. Right atrial pressure was completely restored with 30 ,u g NKH477. The heart rate, which had been decreased with sodium pentobarbital, was not changed with 30 ,u g ouabain, but increased with NKH477 in a dose-dependent manner. However, with 30,ug NKH477, at which the cardiac function curve returned to the control value, the increase in heart rate was only about 12% of the control value and not signi ficant (Table 1) . Table 1 . The combined effects of NKH477 with ouabain on heart rate (HR), the maximum rate of rise in left ventricular pressure (LV dP/dtmax) and right atrial pressure (RAP) in the pentobarbital induced heart failure Propranolol or verapamil-induced heart failure Cardiac function curves obtained from each of the six experiments in propranolol or verapamil-induced heart failure are presented in Figs. 5 and 6, respectively. After the admin istration of propranolol (22 ± 2 mg, mean value ± S.D.) or verapamil (0.66 ± 0.20 mg, mean value ± S.D.), the cardiac function curve was shifted downwards and to the right as was the case with pentobarbital-induced heart failure. Following the addition of NKH477 (10 -100 ,u g), each depressed cardiac function curve was shifted upwards and to the left in a dose-dependent manner. In each heart failure, with 100,ug NKH477, almost complete improvement of depressed cardiac function was accomplished, judging from the cardiac function curves. In propranolol or verapamil-induced heart failure, changes in other cardiac variables (right atrial pressure, LV dP/dtmax and heart rate) were also similar to those in pentobarbital-induced heart failure. Following the addition of NKH477, these changes were all restored in a dose-dependent manner (Table 2) . No arrhythmias were in duced by NKH477 at any of the doses used in each heart failure. At these doses, the in crease in heart rate was only about 12% of the control value and was not statistically signifi cant, and no arrhythmia was induced. Thus, the combination therapy of NKH477 and car diac glycosides may be useful for the treat ment of heart failure, since the cardiotonic effect of NKH477 was additive to that of oua bain. NKH477 may ameliorate the elevation of peripheral resistance induced by cardiac glycosides by virtue of its direct vasodilator effect (6) and also the latter may modify the positive chronotropic effect of the former. NKH477 also improved the cardiac function depressed by propranolol or verapamil as well as the case by pentobarbital. At a dose of 100 ,ug, the cardiac function curves depressed by propranolol or verapamil were completely res tored to the control state. Therefore, NKH477 was equally effective in propranolol-, vera pamil or pentobarbital-induced heart fail ure, suggesting that the mechanism of the positive inotropic effect of NKH477 does not involve the /3-adrenoceptor stimulation or the Ca-agonistic action. Thus, the effect of NKH477 is non-specific for several drug-in duced heart failure models, and hence NKH477 may be useful for the treatment of various types of heart failure. Table 2 . Effects of NKH477 on heart rate (HR), the maximum rate of rise in left ven tricular pressure (LV dP/dtmax) and right atrial pressure (RAP) in propranolol-induced or verapamil-induced heart failure Recently, some of the novel cardiotonics were evaluated for their ability to improve pentobarbital-induced heart failure in the dog heart-lung preparation (7-9). When com pared in the doses that restored the depressed cardiac function curve to the control level, NKH477 appears to be as potent as denopa mine (8) and MCI-154 (7) and more than 100 times more potent than amrinone (9). Amri none failed to restore the depressed cardiac function curve to the control level at the dose of 10 mg, and no more restoration was observed even with 30 mg of amrinone (9). In this respect, NKH477 appears superior to amrinone as a cardiotonic drug. However, although it is difficult to compare directly, NKH477 seems to be slightly more positively chronotropic than amrinone (9) and to be as positively chronotropic as denoparnine (8), when compared at the doses which produce a similar restoration of the cardiac function.
In the present study, NKH477 was cumula tively administered into the blood reservoir, and the effects of NKH477 reached steady levels in 15 to 20 min after each administra tion. On the other hand, forskolin was re ported to reach a steady level of contractile force within 10 min in isolated canine ventricu lar muscle (10). Thus, NKH477 appears to have slower developing effects than forskolin, although the pharmacological properties of the two agents are similar (2, 6). Furthermore, although NKH477 is water-soluble (about 2000 times more water-soluble than forskolin), about 10% non-ionized NKH477 may be pres ent under physiological conditions (pH 7.4), since the pKa value of NKH477 is about 8.46. These findings, taken together, suggest that NKH477, like forskolin, can permeate a mem brane bilayer to act on the intracellular side of the cell plasma membrane.
The present study demonstrated that several drug-induced experimental cardiac failures were completely improved by NKH477, although a slight increase in heart rate was associated with this improvement. The car diotonic effect of NKH477 was additive to that of ouabain. Furthermore, NKH477 in the doses used produced no arrhythmias, although further experiments will be needed to clarify whether the potentially arrhythmogenic action of NKH477 is different from that of catechol amines. In addition, NKH477 has been shown to have a potent vasodilator action (6). These results suggest that NKH477 would be a potentially useful cardiotonic and vasodilator drug.
